Metastasis Archives - Revista Brasileira de Ginecologia e Obstetrícia
, Summary
Rev Bras Ginecol Obstet. 2019;41(4):264-267
, Most endometrial cancers (75%) are diagnosed in early stages (stages I and II), in which abnormal uterine bleeding is the most frequent clinical sign.When the diagnosis is performed in stage IV, the most common sites of metastasis are the lungs, liver and bones. Central nervous system (CNS)metastasis is a rare condition. The aim of this study is to describe a case of uterine papillary serous adenocarcinoma of the endometrium that progressed to brain and bone metastases.
We present the case of a 56-year-old woman with abnormal uterine bleeding and endometrial thickened echo (1.8 cm). A hysteroscopy with biopsy was performed, which identified poor differentiated serous adenocarcinoma of the endometrium. A total abdominal hysterectomy, with pelvic and para-aortic lymphadenectomy, was performed. Analysis of the surgical specimen revealed a grade III uterine papillary serous adenocarcinoma. Adjuvant radio/chemotherapy (carboplatin and paclitaxel-six cycles) was indicated. Sixteen months after the surgery, the patient began to complain of headaches. Brain magnetic resonance imaging demonstrated an expansile mass in the right parietal lobe, suggesting a secondary hematogenous implant subsequently confirmed by biopsy. She underwent surgery for treatment of brain metastasis, followed by radiotherapy. She died 12 months after the brain metastasis diagnosis due to disease progression.
Uterine papillary serous adenocarcinoma of the endometrium has a low propensity to metastasize to the brain. To the best of our knowledge, this is the fifth documented case of uterine papillary serous adenocarcinoma of the endometrium with metastasis to the CNS.
Summary
Rev Bras Ginecol Obstet. 2019;41(4):264-267
, Most endometrial cancers (75%) are diagnosed in early stages (stages I and II), in which abnormal uterine bleeding is the most frequent clinical sign.When the diagnosis is performed in stage IV, the most common sites of metastasis are the lungs, liver and bones. Central nervous system (CNS)metastasis is a rare condition. The aim of this study is to describe a case of uterine papillary serous adenocarcinoma of the endometrium that progressed to brain and bone metastases.
We present the case of a 56-year-old woman with abnormal uterine bleeding and endometrial thickened echo (1.8 cm). A hysteroscopy with biopsy was performed, which identified poor differentiated serous adenocarcinoma of the endometrium. A total abdominal hysterectomy, with pelvic and para-aortic lymphadenectomy, was performed. Analysis of the surgical specimen revealed a grade III uterine papillary serous adenocarcinoma. Adjuvant radio/chemotherapy (carboplatin and paclitaxel-six cycles) was indicated. Sixteen months after the surgery, the patient began to complain of headaches. Brain magnetic resonance imaging demonstrated an expansile mass in the right parietal lobe, suggesting a secondary hematogenous implant subsequently confirmed by biopsy. She underwent surgery for treatment of brain metastasis, followed by radiotherapy. She died 12 months after the brain metastasis diagnosis due to disease progression.
Uterine papillary serous adenocarcinoma of the endometrium has a low propensity to metastasize to the brain. To the best of our knowledge, this is the fifth documented case of uterine papillary serous adenocarcinoma of the endometrium with metastasis to the CNS.
Summary
Rev Bras Ginecol Obstet. 1998;20(8):475-479
DOI 10.1590/S0100-72031998000800008
Purpose: to analyze the frequency of preoperative bilateral synchronic cancer and occult metastases in 454 operable breast cancer patients, at Instituto Nacional de Câncer (Brazil). Methods: the preoperative evaluation consisted of mammography, bone scan with X-ray if necessary, and chest X-ray. 260 (57.3 %) of 454 patients underwent liver echography. We calculated the cost X effectiveness ratio considering only the direct costs (monetary value) and the effectiveness was analyzed based on the number of metastases identifid by the screening tests. Results: we did not find any case of bilateral synchronic cancer, and the frequency of patients with metastasis was 2% (9/454). The diagnosis of bone metastasis was 1.5 % (7/454). The percentage of lung (2/454) and liver (1/260) metastasis was the same, 0.4 %. Most of the patients with metastases were in stage IIIb (44.5 %). The results of the screening tests showed the alteration of the initial clinical stage in 9 patients only (2%). The total cost of the screening tests for the diagnosis of systemic disease in 9 patients, was US$ 131,020.00. The cost of each diagnosed metastasise, for a total of 10 (two were found in one of the patients), was US$ 29,221.85 and the cost/effectiveness ratio was 22.3%. Conclusious: the results showed that screening for metastases in the preoperative clinical staging of breast cancer should be limited to patients symptomatic for systemic disease or in clinical stage III and that the cost/effectiveness ratio of the tests demonstrated a reduced benefit in the preoperative evaluation.
Summary
Rev Bras Ginecol Obstet. 1998;20(8):475-479
DOI 10.1590/S0100-72031998000800008
Purpose: to analyze the frequency of preoperative bilateral synchronic cancer and occult metastases in 454 operable breast cancer patients, at Instituto Nacional de Câncer (Brazil). Methods: the preoperative evaluation consisted of mammography, bone scan with X-ray if necessary, and chest X-ray. 260 (57.3 %) of 454 patients underwent liver echography. We calculated the cost X effectiveness ratio considering only the direct costs (monetary value) and the effectiveness was analyzed based on the number of metastases identifid by the screening tests. Results: we did not find any case of bilateral synchronic cancer, and the frequency of patients with metastasis was 2% (9/454). The diagnosis of bone metastasis was 1.5 % (7/454). The percentage of lung (2/454) and liver (1/260) metastasis was the same, 0.4 %. Most of the patients with metastases were in stage IIIb (44.5 %). The results of the screening tests showed the alteration of the initial clinical stage in 9 patients only (2%). The total cost of the screening tests for the diagnosis of systemic disease in 9 patients, was US$ 131,020.00. The cost of each diagnosed metastasise, for a total of 10 (two were found in one of the patients), was US$ 29,221.85 and the cost/effectiveness ratio was 22.3%. Conclusious: the results showed that screening for metastases in the preoperative clinical staging of breast cancer should be limited to patients symptomatic for systemic disease or in clinical stage III and that the cost/effectiveness ratio of the tests demonstrated a reduced benefit in the preoperative evaluation.
Summary
Rev Bras Ginecol Obstet. 1999;21(1):55-58
DOI 10.1590/S0100-72031999000100009
The aim of this report is to present one case of gestational trophoblastic disease with pulmonary metastases apparently persisting despite the return of beta-human chorionic gonadotropin (beta-hCG) to normal levels after five cycles of chemotherapy (20 mg methotrexate/day for 5 days). The patient was submitted to a video-assisted thoracoscopy and the nodules were excised. Histological examination showed tissue necrosis without evidence of residual tumor. It is important to recognize that persistent nodules in the lungs of patients with metastatic gestational disease after treatment and normal beta-hCG titers may not represent viable tumor but rather necrosis and/or fibrosis.
Summary
Rev Bras Ginecol Obstet. 1999;21(1):55-58
DOI 10.1590/S0100-72031999000100009
The aim of this report is to present one case of gestational trophoblastic disease with pulmonary metastases apparently persisting despite the return of beta-human chorionic gonadotropin (beta-hCG) to normal levels after five cycles of chemotherapy (20 mg methotrexate/day for 5 days). The patient was submitted to a video-assisted thoracoscopy and the nodules were excised. Histological examination showed tissue necrosis without evidence of residual tumor. It is important to recognize that persistent nodules in the lungs of patients with metastatic gestational disease after treatment and normal beta-hCG titers may not represent viable tumor but rather necrosis and/or fibrosis.
Summary
Rev Bras Ginecol Obstet. 2005;27(7):421-424
DOI 10.1590/S0100-72032005000700009
Report of a case of an 83-year-old woman presenting a nodule and skin retraction in the right breast for eight months. On physical examination, a solid nodule of 5 cm was observed, located in the upper-lateral quadrant of the right breast, associated with skin retraction and ipsilateral lymph nodes. Mammographic findings showed irregularly limited nodules of 4 cm in the upper-lateral quadrant of the right breast (bi-rads V). Clinical staging: T2N1M0 (IIB). Surgical treatment included a modified radical mastectomy with axillary dissection levels I, II, and III. Histopathologic evaluation demonstrated the presence of an infiltrating lobular carcinoma measuring 2.5 cm (T2), presence of granulomatous lymphadenitis caused by tuberculosis in level I, II, and III lymph nodes, associated with lobular carcinoma metastasis in a single level I lymph node. Pathologic staging: pT2pN1aM0. The treatment for the axillary tuberculous lymphadenitis was done with rifampin, isoniazid and pyrazinamide for one year. Hormone receptors were positive, and adjuvant therapy was initiated with tamoxifen. During the first year of follow-up the patient had no signal of local recurrence or distant metastases.
Summary
Rev Bras Ginecol Obstet. 2005;27(7):421-424
DOI 10.1590/S0100-72032005000700009
Report of a case of an 83-year-old woman presenting a nodule and skin retraction in the right breast for eight months. On physical examination, a solid nodule of 5 cm was observed, located in the upper-lateral quadrant of the right breast, associated with skin retraction and ipsilateral lymph nodes. Mammographic findings showed irregularly limited nodules of 4 cm in the upper-lateral quadrant of the right breast (bi-rads V). Clinical staging: T2N1M0 (IIB). Surgical treatment included a modified radical mastectomy with axillary dissection levels I, II, and III. Histopathologic evaluation demonstrated the presence of an infiltrating lobular carcinoma measuring 2.5 cm (T2), presence of granulomatous lymphadenitis caused by tuberculosis in level I, II, and III lymph nodes, associated with lobular carcinoma metastasis in a single level I lymph node. Pathologic staging: pT2pN1aM0. The treatment for the axillary tuberculous lymphadenitis was done with rifampin, isoniazid and pyrazinamide for one year. Hormone receptors were positive, and adjuvant therapy was initiated with tamoxifen. During the first year of follow-up the patient had no signal of local recurrence or distant metastases.
Summary
Rev Bras Ginecol Obstet. 2003;25(8):609-611
DOI 10.1590/S0100-72032003000800011
Carcinoma of the uterine cervix is a common neoplasm; however skin metastasis from carcinoma of the uterine cervix is a very rare occurrence, varying from 0.1% to 2%. The common primary sites in patients with skin metastasis are the breast, lung, large intestine and ovary. The interval between the diagnosis of cervical cancer and skin lesions ranges from 0 to 69 months, and they present as nodules in 86,7%. Skin metastasis represents a late manifestation of advanced disease with poor prognosis. We present a case of scalp metastasis from carcinoma of the uterine cervix . The patient was 43 years old, had a diagnosis of undifferentiated epidermoid carcinoma of the uterine cervix. Six months after radical surgery she presented with vaginal recurrence, being treated with pelvic radiotherapy. Four months later three painless metastatic nodules appeared at the scalp. The patient underwent chemotherapy with total regression of the scalp lesions.
Summary
Rev Bras Ginecol Obstet. 2003;25(8):609-611
DOI 10.1590/S0100-72032003000800011
Carcinoma of the uterine cervix is a common neoplasm; however skin metastasis from carcinoma of the uterine cervix is a very rare occurrence, varying from 0.1% to 2%. The common primary sites in patients with skin metastasis are the breast, lung, large intestine and ovary. The interval between the diagnosis of cervical cancer and skin lesions ranges from 0 to 69 months, and they present as nodules in 86,7%. Skin metastasis represents a late manifestation of advanced disease with poor prognosis. We present a case of scalp metastasis from carcinoma of the uterine cervix . The patient was 43 years old, had a diagnosis of undifferentiated epidermoid carcinoma of the uterine cervix. Six months after radical surgery she presented with vaginal recurrence, being treated with pelvic radiotherapy. Four months later three painless metastatic nodules appeared at the scalp. The patient underwent chemotherapy with total regression of the scalp lesions.
Summary
Rev Bras Ginecol Obstet. 2000;22(7):449-454
DOI 10.1590/S0100-72032000000700008
Purpose: to evaluate the prognostic value of estrogen receptor and p53 and c-erbB-2 proteins in lymph node-negative breast cancer. Methods: an immunohistochemical study was made in paraffin-embedded tissues from the file of the Instituto de Pesquisas Cito-Oncológicas of the Fundação Faculdade Federal de Ciências Médicas de Porto Alegre of fifty cases of postmenopausal women, who were treated at the Irmandade da Santa Casa de Misericórdia de Porto Alegre and at the Santa Rita Hospital from 1990 to 1994. For statistical analysis c² with Yates correction, as well as exact Fisher tests were used and Kaplan Meier curves compared with log-rank test. The mean follow-up of the patients was 3.6 years (3.1-4.5). Of the 50 cases, 14 showed recurrence during the period of follow-up. Results: the mean age was 61 years (46-78). Modified radical mastectomy was performed in 35 patients (70%) and 15 (30%) were submitted to lumpectomy/axillary dissection and postoperative radiation therapy. Fifty percent of the patients who showed recurrence did it in the first three years after the diagnosis. The mean size of the tumor was 2.8 cm (1.98-3.13) and the most frequent histological type was invasive ductal carcinoma of no special type (92%), according to the Bloom and Richardson graduation, 3 being stage I (6.6%), 35 stage II (76%) and 8 stage III (17.4%). In the tumors with recurrence, there was no grade I, 9 stage II (25.7%) and 3 stage III (37.5%). In relation to the prognosis, the disease-free interval was less when there was association of a poorly differentiated tumor with negative estrogen receptor (p = 0.006), positive p53 (p = 0.006) and positive c-erbB-2 (p = 0.001). Conclusion: postmenopausal women with lymph node-negative breast cancer showed worse prognosis in relation to disease-free interval when they presented poorly differentiated tumor associated with negative estrogen receptor, positive p53 and positive c-erbB-2.
Summary
Rev Bras Ginecol Obstet. 2000;22(7):449-454
DOI 10.1590/S0100-72032000000700008
Purpose: to evaluate the prognostic value of estrogen receptor and p53 and c-erbB-2 proteins in lymph node-negative breast cancer. Methods: an immunohistochemical study was made in paraffin-embedded tissues from the file of the Instituto de Pesquisas Cito-Oncológicas of the Fundação Faculdade Federal de Ciências Médicas de Porto Alegre of fifty cases of postmenopausal women, who were treated at the Irmandade da Santa Casa de Misericórdia de Porto Alegre and at the Santa Rita Hospital from 1990 to 1994. For statistical analysis c² with Yates correction, as well as exact Fisher tests were used and Kaplan Meier curves compared with log-rank test. The mean follow-up of the patients was 3.6 years (3.1-4.5). Of the 50 cases, 14 showed recurrence during the period of follow-up. Results: the mean age was 61 years (46-78). Modified radical mastectomy was performed in 35 patients (70%) and 15 (30%) were submitted to lumpectomy/axillary dissection and postoperative radiation therapy. Fifty percent of the patients who showed recurrence did it in the first three years after the diagnosis. The mean size of the tumor was 2.8 cm (1.98-3.13) and the most frequent histological type was invasive ductal carcinoma of no special type (92%), according to the Bloom and Richardson graduation, 3 being stage I (6.6%), 35 stage II (76%) and 8 stage III (17.4%). In the tumors with recurrence, there was no grade I, 9 stage II (25.7%) and 3 stage III (37.5%). In relation to the prognosis, the disease-free interval was less when there was association of a poorly differentiated tumor with negative estrogen receptor (p = 0.006), positive p53 (p = 0.006) and positive c-erbB-2 (p = 0.001). Conclusion: postmenopausal women with lymph node-negative breast cancer showed worse prognosis in relation to disease-free interval when they presented poorly differentiated tumor associated with negative estrogen receptor, positive p53 and positive c-erbB-2.
